BioXcel Therapeutics Inc
BTAI
Get informed when a big investor buys or sells
+ FollowMarket Cap$37.05M
Close$
$-1.08
182.6% downside
Current Fair Value
182.6% downsideOvervalued by 182.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $37.05 Million |
|---|---|
| Enterprise Value | $120.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.73 |
| Beta | 0.32 |
| Outstanding Shares | 12,208,000 |
Return
| Return on Equity | 71.38% |
|---|---|
| Return on Assets | -221.41% |
| Return on Invested Capital | 299.79% |
Valuation & Multiples
| P/E Ratio | -0.18 |
|---|---|
| PEG | -0.24 |
| Price to Sales | - |
| Price to Book Ratio | -0.15 |
| Enterprise Value to Revenue | 176.71 |
| Enterprise Value to EBIT | -1.91 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.83 |
| Debt to Equity | -0.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$381,491
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$403,315
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 44.57%▲ 19.65% |
|---|---|
| Total Invested | $7.28M▲ 28.45% |
| Investors Holding | 40▼ 1.00% |
ESG Score
No data
About BioXcel Therapeutics Inc
CEO: Vimal Mehta